Popular search terms:
Search Results Label
19 results found-
Seqirus | Influenza Expertise
Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.seqirus.com/expertise -
Seqirus | Global Manufacturing Network
Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.
https://www.seqirus.com/manufacturing/global-manufacturing-network -
Seqirus | Vaccine Technologies
Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.
https://www.seqirus.com/manufacturing/technologies -
Seqirus | Meet Our Leadership
Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.
https://www.seqirus.com/our-company/leadership -
Seqirus | Research & Development Efforts
Seqirus is working tirelessly to optimise our technology and implement transformational long-term approaches to influenza pandemic preparedness.
https://www.seqirus.com/r-and-d -
Seqirus Methodological Statement for EFPIA CY2017
29 May 2018 Seqirus Guidelines for Abiding by the EFPIA Transparency Code as of the 2017 Reporting Year Preamble Seqirus is the new global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccines business formerly owned by Novartis AG.
https://www.seqirus.com/-/media/seqirus/pdfs/seqirus-methodological-statement-for-efpia-cy2017.pdf -
Microsoft Word - Seqirus Methodological Statement for EFPIA CY2018 - No Watermark
Seqirus is the new global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccines business formerly owned by Novartis AG.
https://www.seqirus.com/-/media/seqirus/pdfs/seqirus-methodological-statement-for-efpia-cy2018.pdf -
Seqirus | Technical Development
Understand our aim to develop the next generation of influenza vaccines and how we're working to unite product platforms across the globe.
https://www.seqirus.com/manufacturing/technical-development -
Case Study: Myanmar
We produce antivenoms for Australia's most dangerous creatures and Q fever vaccines to protect people working with livestock. Learn about these unique products.
https://www.seqirus.com/expertise/antivenom-and-q-fever-vaccines/case-study-myanmar -
Seqirus | In-Licensing & Partnerships
Seqirus is the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more about our pharmaceutical partnership capabilities.
https://www.seqirus.com/expertise/in-licensing